ATTRibute-CM trial of acoramidis in symptomatic transthyretin amyloid cardiomyopathy

Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing Acoramidis with Placebo (2 arms). Primary endpoints: Change from baseline to Month 12 in 6-minute walk test distance and Hierarchical combination of all-cause mortality, cardiovascular-related hospitalization, and change from baseline in 6-minute walk test over 30 months. Started Feb 2020; status: completed.